Business Context and Reporting Period
This Form 8-K Current Report was filed by Harvard Bioscience, Inc. on May 14, 2013. The filing reports a significant corporate governance event involving the departure of the Chief Executive Officer and the appointment of an interim successor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial statement data.
Material Changes
- Executive Departure: Chane Graziano retired and resigned as Chief Executive Officer and as a member of the Board of Directors effective May 14, 2013.
- Interim Appointment: David Green, the current President and a Board member since March 1996, was appointed Interim Chief Executive Officer effective May 14, 2013.
- Search for Permanent CEO: The Board immediately commenced a search to hire a permanent Chief Executive Officer.
Guidance, Outlook, and Risks
The filing states that Mr. Graziano has not expressed any disagreement with the Corporation regarding operations, policies, or practices. No financial guidance, outlook, or specific risk factors were disclosed in this document. A press release dated May 15, 2013, is included as Exhibit 99.1 but its content is not detailed in the filing text provided.
Investor Verification Checklist
- Verify the timeline and criteria for the search for a permanent Chief Executive Officer.
- Review the attached press release (Exhibit 99.1) for additional context on the leadership transition.
- Monitor subsequent filings for the appointment of a permanent CEO and any changes to the Board composition.
- Check the company's most recent 10-K or 10-Q for the latest financial performance data, as this 8-K contains none.